Roche will close 454 Life Sciences and stop making its gene sequencing tech

Roche ($RHHBY) has begun to close down subsidiary 454 Life Sciences and will lay off its 130 employees through 2015, Bio-IT World reported. The closing of the division signifies a shift of Roche's diagnostics arm to a smaller role in gene sequencing, continuing a number of gene sequencing-related downsizing measures enacted over the last year, the article noted. Roche will still maintain an exclusive licensing deal with Pacific Biosciences for new in vitro diagnostics products. Roche scooped up 454 Life Sciences from CuraGen in 2007 for about $155 million, when the company was at the forefront of gene sequencing technology and trends. Story | More from FierceBiotech IT | FierceDiagnostics

Suggested Articles

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.

Insulet announced new agreements with Abbott and Dexcom to connect their continuous glucose monitors with its upcoming tubeless, digital insulin pump,